US · Healthcare · Biotechnology
EPS came in at -0.35 against a street estimate of -0.26 — a miss of 34.6%.
Analysts rate Janux Therapeutics Inc a strong buy (16 buy, 1 hold, 1 sell out of 18) with an average price target of $32.07.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 18.30% |
| BlackRock Inc | 10.03% |
| Prosight Management, LP | 6.22% |
| State Street Corp | 4.92% |
| FMR Inc | 3.95% |
| Federated Hermes Inc | 3.85% |
| Point72 Asset Management, L.P. | 3.26% |
| Vanguard Capital Management, LLC | 3.04% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Janux Therapeutics is a clinical-stage biopharmaceutical company with no product revenue to date. • Nine-month 2026 collaboration | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Cash, cash equivalents and short-term investments totaled $945.7 million as of September 30, 2026, compared with $966.6 million as | 2026-11-05 |
| Quarterly report · Q2 2026 JANUX THERAPEUTICS, INC. – FORM 10-Q SUMMARY For Quarterly Period Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and equivalents: $27.8 million (d | 2026-08-06 |
| Results announced · Q3 2026 JANUX THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash and short-term investments: $970.9 million as of June 30, 2026 (vs. $96 | 2026-08-06 |
| Company announcement · Q2 2026 JANUX THERAPEUTICS, INC. - 8-K SUMMARY OTHER NOTABLE POINTS • Chief Medical Officer William Go, M.D., Ph.D. departed the company on June 23, 2026 un | 2026-06-23 |
| Shareholder vote results · Q2 2026 JANUX THERAPEUTICS, INC. — 8-K SUMMARY HEADLINE NUMBERS • Record date for 2026 Annual Meeting: April 17, 2026 • Total shares outstanding and entitle | 2026-06-12 |
| Quarterly report · Q1 2026 JANUX THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Assets: $1,028.2 million as of March 31, 2026 (up from $1,001.6 million at | 2026-05-07 |
| Results announced · Q2 2026 JANUX THERAPEUTICS Q1 2026 FINANCIAL RESULTS HEADLINE NUMBERS • Cash and short-term investments: $956.4 million (March 31, 2026) vs. $966.6 million | 2026-05-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Janux Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.